Effect of endothelin(A)-receptor antagonist BQ-123 and phosphoramidon on cerebral vasospasm

F. Cosentino, E. G. McMahon, J. S. Carter, Zvonimir S Katusic

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

The present study was designed to determine whether an endothelin(A) (ET(A))-receptor antagonist BQ-123 (cyclo[Dtrp, Dasp, pro-D-Val-Leu]) or an ET-converting enzyme inhibitor phosphoramidon may prevent development of cerebral vasospasm after subarachnoid hemorrhage (SAH). A 'double hemorrhage' canine model of the disease was used (n = 17 dogs), and the degree of vasospasm of the basilar artery was assessed by angiography. Mongrel dogs of either sex were divided into three experimental groups: animals treated with daily intracisternal injections of BQ-123 (10-4 M; n = 6) or phosphoramidon (2 x 10-4 M; n = 6) and control animals treated with saline solution (n = 5). Diameter of basilar arteries in animals treated with saline solution was reduced by SAH to 56 ± 7% of control diameter. BQ-123 and phosphoramidon did not significantly affect SAH-induced vasospasm (diameters were 62 ± 0% and 56 ± 10% of control diameters for BQ-123 and phosphoramidon, respectively). In contrast, in isolated canine basilar arteries BQ-123 (10-5 M) selectively inhibited concentration-dependent contractions to ET-1 (10-11-3 x 108 M; n = 5). Levels of immunoreactive ET in plasma and cerebrospinal fluid were not affected by development of vasospasm. These results suggest that intracisternal injections of ET(A)-receptor antagonist or phosphoramidon cannot prevent SAH-induced cerebral vasospasm and that ET- 1 may not be the major mediator responsible for the decrease in cerebral arterial diameter associated with SAH.

Original languageEnglish (US)
JournalJournal of Cardiovascular Pharmacology
Volume22
Issue numberSUPPL. 8
StatePublished - 1993

Fingerprint

Intracranial Vasospasm
Subarachnoid Hemorrhage
Basilar Artery
Sodium Chloride
valylleucine
Dogs
Dog Diseases
Injections
Enzyme Inhibitors
Cerebrospinal Fluid
Canidae
Angiography
phosphoramidon
Endothelin A Receptor Antagonists
cyclo(Trp-Asp-Pro-Val-Leu)
Hemorrhage

Keywords

  • BQ- 123
  • Cerebral vasospasm
  • Endothelin(A) receptor
  • Phosphoramidon
  • Subarachnoid hemorrhage

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

Effect of endothelin(A)-receptor antagonist BQ-123 and phosphoramidon on cerebral vasospasm. / Cosentino, F.; McMahon, E. G.; Carter, J. S.; Katusic, Zvonimir S.

In: Journal of Cardiovascular Pharmacology, Vol. 22, No. SUPPL. 8, 1993.

Research output: Contribution to journalArticle

@article{f92a9377845e4a78a2dd4efe7731197a,
title = "Effect of endothelin(A)-receptor antagonist BQ-123 and phosphoramidon on cerebral vasospasm",
abstract = "The present study was designed to determine whether an endothelin(A) (ET(A))-receptor antagonist BQ-123 (cyclo[Dtrp, Dasp, pro-D-Val-Leu]) or an ET-converting enzyme inhibitor phosphoramidon may prevent development of cerebral vasospasm after subarachnoid hemorrhage (SAH). A 'double hemorrhage' canine model of the disease was used (n = 17 dogs), and the degree of vasospasm of the basilar artery was assessed by angiography. Mongrel dogs of either sex were divided into three experimental groups: animals treated with daily intracisternal injections of BQ-123 (10-4 M; n = 6) or phosphoramidon (2 x 10-4 M; n = 6) and control animals treated with saline solution (n = 5). Diameter of basilar arteries in animals treated with saline solution was reduced by SAH to 56 ± 7{\%} of control diameter. BQ-123 and phosphoramidon did not significantly affect SAH-induced vasospasm (diameters were 62 ± 0{\%} and 56 ± 10{\%} of control diameters for BQ-123 and phosphoramidon, respectively). In contrast, in isolated canine basilar arteries BQ-123 (10-5 M) selectively inhibited concentration-dependent contractions to ET-1 (10-11-3 x 108 M; n = 5). Levels of immunoreactive ET in plasma and cerebrospinal fluid were not affected by development of vasospasm. These results suggest that intracisternal injections of ET(A)-receptor antagonist or phosphoramidon cannot prevent SAH-induced cerebral vasospasm and that ET- 1 may not be the major mediator responsible for the decrease in cerebral arterial diameter associated with SAH.",
keywords = "BQ- 123, Cerebral vasospasm, Endothelin(A) receptor, Phosphoramidon, Subarachnoid hemorrhage",
author = "F. Cosentino and McMahon, {E. G.} and Carter, {J. S.} and Katusic, {Zvonimir S}",
year = "1993",
language = "English (US)",
volume = "22",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 8",

}

TY - JOUR

T1 - Effect of endothelin(A)-receptor antagonist BQ-123 and phosphoramidon on cerebral vasospasm

AU - Cosentino, F.

AU - McMahon, E. G.

AU - Carter, J. S.

AU - Katusic, Zvonimir S

PY - 1993

Y1 - 1993

N2 - The present study was designed to determine whether an endothelin(A) (ET(A))-receptor antagonist BQ-123 (cyclo[Dtrp, Dasp, pro-D-Val-Leu]) or an ET-converting enzyme inhibitor phosphoramidon may prevent development of cerebral vasospasm after subarachnoid hemorrhage (SAH). A 'double hemorrhage' canine model of the disease was used (n = 17 dogs), and the degree of vasospasm of the basilar artery was assessed by angiography. Mongrel dogs of either sex were divided into three experimental groups: animals treated with daily intracisternal injections of BQ-123 (10-4 M; n = 6) or phosphoramidon (2 x 10-4 M; n = 6) and control animals treated with saline solution (n = 5). Diameter of basilar arteries in animals treated with saline solution was reduced by SAH to 56 ± 7% of control diameter. BQ-123 and phosphoramidon did not significantly affect SAH-induced vasospasm (diameters were 62 ± 0% and 56 ± 10% of control diameters for BQ-123 and phosphoramidon, respectively). In contrast, in isolated canine basilar arteries BQ-123 (10-5 M) selectively inhibited concentration-dependent contractions to ET-1 (10-11-3 x 108 M; n = 5). Levels of immunoreactive ET in plasma and cerebrospinal fluid were not affected by development of vasospasm. These results suggest that intracisternal injections of ET(A)-receptor antagonist or phosphoramidon cannot prevent SAH-induced cerebral vasospasm and that ET- 1 may not be the major mediator responsible for the decrease in cerebral arterial diameter associated with SAH.

AB - The present study was designed to determine whether an endothelin(A) (ET(A))-receptor antagonist BQ-123 (cyclo[Dtrp, Dasp, pro-D-Val-Leu]) or an ET-converting enzyme inhibitor phosphoramidon may prevent development of cerebral vasospasm after subarachnoid hemorrhage (SAH). A 'double hemorrhage' canine model of the disease was used (n = 17 dogs), and the degree of vasospasm of the basilar artery was assessed by angiography. Mongrel dogs of either sex were divided into three experimental groups: animals treated with daily intracisternal injections of BQ-123 (10-4 M; n = 6) or phosphoramidon (2 x 10-4 M; n = 6) and control animals treated with saline solution (n = 5). Diameter of basilar arteries in animals treated with saline solution was reduced by SAH to 56 ± 7% of control diameter. BQ-123 and phosphoramidon did not significantly affect SAH-induced vasospasm (diameters were 62 ± 0% and 56 ± 10% of control diameters for BQ-123 and phosphoramidon, respectively). In contrast, in isolated canine basilar arteries BQ-123 (10-5 M) selectively inhibited concentration-dependent contractions to ET-1 (10-11-3 x 108 M; n = 5). Levels of immunoreactive ET in plasma and cerebrospinal fluid were not affected by development of vasospasm. These results suggest that intracisternal injections of ET(A)-receptor antagonist or phosphoramidon cannot prevent SAH-induced cerebral vasospasm and that ET- 1 may not be the major mediator responsible for the decrease in cerebral arterial diameter associated with SAH.

KW - BQ- 123

KW - Cerebral vasospasm

KW - Endothelin(A) receptor

KW - Phosphoramidon

KW - Subarachnoid hemorrhage

UR - http://www.scopus.com/inward/record.url?scp=0027764534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027764534&partnerID=8YFLogxK

M3 - Article

VL - 22

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - SUPPL. 8

ER -